Drug-to-Antibody Ratio (DAR) Calculation of Antibody-Drug Conjugates (ADCs)

Significance of the Topic

Antibody-drug conjugates (ADCs) are emerging as a powerful class of targeted biotherapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic small molecules. Drug-to-antibody ratio (DAR) is a critical quality attribute, influencing efficacy, pharmacokinetics, and safety profiles. Accurate, reproducible DAR measurement is essential for process development, quality control, and regulatory compliance in ADC research and manufacturing.

Study Objectives and Overview

This application note describes a streamlined workflow for DAR determination of both intact and reduced ADCs using automated sample preparation and a novel DAR calculator software. Key goals were to increase throughput, reduce operator variability, and simplify data processing by integrating Agilent AssayMAP Bravo automation, enzymatic deglycosylation, and high-resolution LC/MS analysis.

Methodology and Sample Preparation

ADC samples were aliquoted into 96-well plates and processed under four conditions: intact glycosylated, intact deglycosylated, reduced glycosylated, and reduced deglycosylated. The automated AssayMAP Bravo platform performed buffer addition, reduction with DTT, and deglycosylation with rapid PNGase F in parallel. Reactions were sealed and incubated at 50 °C for 10 minutes, minimizing hands-on time and ensuring consistent reaction conditions across eight replicates per condition.

Used Instrumentation

• AssayMAP Bravo automated sample preparation system
• Agilent 1290 Infinity UHPLC with Agilent PLRP-S 2.1 × 150 mm, 1000 Å column
• Agilent 6550 iFunnel Q-TOF mass spectrometer with Dual Jet Stream ESI source
• Agilent MassHunter Qualitative Analysis and BioConfirm software with DAR Calculator

Main Results and Discussion

Intact ADCs:

• Intact glycosylated ADCs eluted in <1 minute; nine peak groups corresponding to D0–D8 with major glycoforms G0F/G0F, G0F/G1F, G1F/G1F.
• Intact deglycosylation simplified spectra, yielding ten DAR peak groups (D0–D9) and approximately 2× higher signal intensity.
• Average DAR values were 3.60 (CV = 0%) for glycosylated and 3.88 (CV = 1.1%) for deglycosylated ADCs.

Reduced ADCs:

• Light-chain species (D0–D3) and heavy-chain species (D0–D4) were resolved with charge states +6 to +27 (light) and +13 to +53 (heavy).
• Deglycosylation removed glycoform heterogeneity while preserving DAR distribution.
• Combined DAR for reduced ADCs was 3.23 (CV = 2.2%) for glycosylated and 3.21 (CV = 2.6%) for deglycosylated samples.

Benefits and Practical Applications

The automated workflow delivers high reproducibility, reduced hands-on time, and scalable throughput (8–96 samples). Rapid deglycosylation within one hour and robust LC/MS analysis support streamlined ADC characterization during early discovery, process optimization, and QC release testing.

Future Trends and Opportunities

Integration of enhanced automation, real-time data analytics, and machine learning-driven peak deconvolution will further accelerate DAR determination. Expansion to other bioconjugate classes, native mass analysis, and multi-attribute monitoring are anticipated advances for comprehensive biotherapeutic characterization.

Conclusion

The combination of AssayMAP Bravo automated sample preparation, rapid PNGase F deglycosylation, high-resolution UHPLC-Q-TOF analysis, and dedicated DAR calculator software provides a robust, high-throughput solution for accurate ADC DAR measurement. This workflow minimizes variability, simplifies data interpretation, and supports the rigorous demands of ADC development and manufacture.

References

• Perez H.L.; et al. Antibody-drug conjugates: current status and future directions. Drug Discovery Today 2014, 19(7), 869–881.
• Basa L. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS. In Antibody Drug Conjugates; Dury L., Ed.; Methods in Molecular Biology; Humana Press: New York, 2013; Vol. 1045, pp. 285–293.